# Metagenomi Therapeutics, Inc.: overview MGX · Nasdaq · CIK 1785279 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/mgx.md) · [Financials](/companies/mgx/financials.md) · [Filings](/companies/mgx/filings.md) · [Insiders](/companies/mgx/insiders.md) Latest reported revenue: [$1.2m](/filings/0001193125-26-216774.md) for Q1 FY2026, three months to 2026-03-31, from the 10-Q filed May 11, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-216774). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [11.5](/filings/0001193125-25-276150.md) | [9.6 d](/filings/0001193125-26-093976.md) | [4.1](/filings/0001193125-26-216774.md) | [8.5](/filings/0000950170-25-107308.md) | [8.7](/filings/0001193125-25-276150.md) | [3.9 d](/filings/0001193125-26-093976.md) | [1.2](/filings/0001193125-26-216774.md) | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(194.4%)](/filings/0001193125-25-276150.md) | [(214.5%) d](/filings/0001193125-26-093976.md) | [(674.1%)](/filings/0001193125-26-216774.md) | [(246.5%)](/filings/0001193125-26-342400.md) | [(263.8%)](/filings/0001193125-25-276150.md) | [(623.0%) d](/filings/0001193125-26-093976.md) | [(1970.1%)](/filings/0001193125-26-216774.md) | not reported | | Net margin | % | [(163.0%)](/filings/0001193125-25-276150.md) | [(243.4%) d](/filings/0001193125-26-093976.md) | [(606.7%)](/filings/0001193125-26-342400.md) | [(233.9%)](/filings/0001193125-26-342400.md) | [(235.5%)](/filings/0001193125-25-276150.md) | [(576.0%) d](/filings/0001193125-26-093976.md) | [(1847.7%)](/filings/0001193125-26-342400.md) | not reported | | Diluted EPS | $ per share | [(0.51)](/filings/0001193125-25-276150.md) | not reported | [(0.68)](/filings/0001193125-26-216774.md) | [(0.54)](/filings/0001193125-26-342400.md) | [(0.55)](/filings/0001193125-25-276150.md) | not reported | [(0.61)](/filings/0001193125-26-216774.md) | [(0.73)](/filings/0001193125-26-342400.md) | | Free cash flow | $m | [(27.8) d](/filings/0001193125-25-276150.md) | [(26.6) d](/filings/0001193125-26-093976.md) | [(23.1)](/filings/0001193125-26-216774.md) | [(21.4) d](/filings/0001193125-26-342400.md) | [(21.3) d](/filings/0001193125-25-276150.md) | [(23.6) d](/filings/0001193125-26-093976.md) | [(21.2)](/filings/0001193125-26-216774.md) | [(19.6) d](/filings/0001193125-26-342400.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | | Revenue | $m | [44.8](/filings/0000950170-25-040217.md) | [52.3](/filings/0001193125-26-093976.md) | [25.2](/filings/0001193125-26-093976.md) | | Gross margin | % | not reported | not reported | not reported | | Operating margin | % | [(175.4%)](/filings/0000950170-25-040217.md) | [(170.0%)](/filings/0001193125-26-093976.md) | [(380.9%)](/filings/0001193125-26-093976.md) | | Net margin | % | [(152.5%)](/filings/0000950170-25-040217.md) | [(149.3%)](/filings/0001193125-26-093976.md) | [(348.5%)](/filings/0001193125-26-093976.md) | | Diluted EPS | $ per share | [(20.05)](/filings/0000950170-25-040217.md) | [(2.36)](/filings/0001193125-26-093976.md) | [(2.36)](/filings/0001193125-26-093976.md) | | Free cash flow | $m | [(101)](/filings/0000950170-25-040217.md) | [(112)](/filings/0001193125-26-093976.md) | [(89.5)](/filings/0001193125-26-093976.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/mgx/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $1.3m | 1,077,700 | | Added +19,756 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $883.5k | 742,400 | | Reduced −45,500 | | [Catalio Capital Management, LP](/funds/1958125.md) | 2026-06-30 | $629.5k | 528,993 | | Unchanged | | [Peapod Lane Capital LLC](/funds/2050979.md) | 2026-06-30 | $624.8k | 525,024 | | Added +8,263 | | [TWO SIGMA INVESTMENTS, LP](/funds/1179392.md) | 2026-06-30 | $611.3k | 513,701 | | Added +16,934 | | [BRIDGEWAY CAPITAL MANAGEMENT, LLC](/funds/1107261.md) | 2026-06-30 | $476.4k | 400,300 | | Added +4,500 | | [WELLS FARGO & COMPANY/MN](/funds/72971.md) | 2026-06-30 | $451.6k | 379,508 | | Added +177,370 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $343.7k | 288,665 | | Reduced −69,535 | | [PURA VIDA INVESTMENTS, LLC](/funds/1590144.md) | 2026-06-30 | $314.6k | 264,391 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $306.6k | 257,631 | | Added +27,497 | ## Recent filings [All 154 filings](/companies/mgx/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-22 | 20:49 ET | [8-K](/filings/0001193125-26-397037.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-397037 | | 2026-08-10 | 16:12 ET | [10-Q](/filings/0001193125-26-342400.md) | Quarterly report, period 2026-06-30 | 0001193125-26-342400 | | 2026-08-10 | 16:10 ET | [8-K](/filings/0001193125-26-342388.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-342388 | | 2026-06-10 | 18:11 ET | [8-K](/filings/0001193125-26-264392.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results | 0001193125-26-264392 | | 2026-05-11 | 16:10 ET | [10-Q](/filings/0001193125-26-216774.md) | Quarterly report, period 2026-03-31 | 0001193125-26-216774 | | 2026-05-11 | 16:09 ET | [8-K](/filings/0001193125-26-216763.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-216763 | | 2026-04-27 | 16:55 ET | [DEF 14A](/filings/0001193125-26-182325.md) | Proxy statement, period 2026-04-21 | 0001193125-26-182325 | | 2026-03-05 | 16:14 ET | [10-K](/filings/0001193125-26-093976.md) | Annual report, period 2025-12-31 | 0001193125-26-093976 | | 2026-03-05 | 16:09 ET | [8-K](/filings/0001193125-26-093943.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-093943 | | 2026-01-12 | 09:27 ET | [8-K](/filings/0001193125-26-009928.md) | 5.03 Amendment to articles or bylaws; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-009928 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-093976.md), filed Mar 5, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1785279 - Tickers: MGX - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: not reported - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.